Tuesday, 19 Jun 2018

You are here

IBD Associated with Increased risk of Autoimmune and Inflammatory Diseases

A registry based study has shown higher rates of immune mediated diseases (IMD) in patients with inflammatory bowel disease (IBD).

Researchers examined 47325 IBD patients from the Danish National Patient Registry and compared them to controls from a civilian registry and used ICD 10 codes to identify the diagnoses observed.

Overall they found 20 different IMDs were found to be significantly more frequent in the IBD group - 16 associated with ulcerative colitis (UC) and 12 with Crohns disease (CD).  Having IBD showed significantly increased ORs of having:

  • primary sclerosing cholangitis (PSC),
  • celiac disease,
  • type 1 diabetes (T1D),
  • sarcoidosis,
  • asthma,
  • iridocyclitis,
  • psoriasis,
  • pyoderma gangrenosum,
  • rheumatoid arthritis,
  • ankylosing spondylitis.

Disorders seen predominantly with UC  were autoimmune hepatitis, primary biliary cholangitis, Grave's disease, polymyalgia rheumatica, temporal arteritis , and atrophic gastritis.

Restricted to CD were psoriatic arthritis and episcleritis.

Restricted to women with UC were atrophic gastritis, rheumatoid arthritis, temporal arteritis, and polymyalgia rheumatica.

Restricted to women with CD were episcleritis, rheumatoid arthritis, and psoriatic arthritis.

The only disease restricted to men was sarcoidosis.

Considerable overlap exists between these IMDs and IBD.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

The Microbiome and Lupus Connection Reviewed

In the current issue of the New England Journal of Medicine, Drs. James Rosenbaum and Gregg Silverstein review the pathogenesis of systemic lupus erythematosus (SLE) from the viewpoint of a dysbiolsis.

The complexity of the trillions of organisms that constitute our microbiome underscores its multiplicity of functions, including nutrient, metabolic and immune shaping functions.

SPAR Predicts ILD Progression in Systemic Sclerosis

The development and progression of interstitial lung disease in systemic sclerosis can be an ominous finding. A new analysis of two independent clinical trial cohorts shows that oxygen saturation (SpO2) < 94% after 6 minute walk time (6MWT) and the presence of arthritis predicted the development of ILD in SSc.

Low Disease Activity in Lupus Limits Damage

Patients with systemic lupus erythematosus (SLE) who were assessed as being in a low disease activity state during more than half of clinical visits had a decrease in organ damage events of approximately 50%, a retrospective study found.

Long Term Remission in SLE is Possible?

Researchers from the Toronto Lupus Clinic have described an atypical “monophasic” course in a small number (7.5%) of systemic lupus erythematosus (SLE) patients who achieved and sustained clinical remission, with most off of all medications for an average of 18 years.

Their inception SLE cohort includes patients enrolled within 18 mos of diagnosis.

Ustekinumab: A Novel Intervention in Giant Cell Arteritis

Treatment of refractory giant cell arteritis (GCA) with ustekinumab (Stelara) showed therapeutic promise as a steroid-sparing agent in a small, open-label study, Irish researchers reported.